Incannex Healthcare Limited shares are trading higher after the company received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence clinical trial on IHL-42X.
Portfolio Pulse from Benzinga Newsdesk
Incannex Healthcare Limited has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence clinical trial on IHL-42X, causing its shares to trade higher.
July 06, 2023 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex Healthcare's shares are trading higher after receiving approval to commence a clinical trial on IHL-42X.
The approval to commence a clinical trial on IHL-42X is a positive development for Incannex Healthcare. This could potentially lead to new revenue streams for the company if the trial is successful, which is likely why the shares are trading higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100